- 日
- 関
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/04/30 20:31:54」(JST)
[Wiki en表示]
Fosfestrol
|
| Systematic (IUPAC) name |
[4-[4-(4-phosphonooxyphenyl)hex-3-en-3-yl]
phenoxy]phosphonic acid |
| Clinical data |
| Trade names |
Honvan |
| AHFS/Drugs.com |
International Drug Names |
| Legal status |
℞ Prescription only |
| Identifiers |
| CAS number |
13425-53-1 N |
| ATC code |
L02AA04 |
| PubChem |
CID 3032325 |
| ChemSpider |
2297327 Y |
| UNII |
A0E0NMA80F Y |
| KEGG |
D00946 Y |
| Chemical data |
| Formula |
C18H22O8P2 |
| Mol. mass |
428.310 g/mol |
SMILES
- O=P(Oc1ccc(cc1)\C(=C(\c2ccc(OP(=O)(O)O)cc2)CC)CC)(O)O
|
InChI
-
InChI=1S/C18H22O8P2/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24/h5-12H,3-4H2,1-2H3,(H2,19,20,21)(H2,22,23,24)/b18-17+ Y
Key:NLORYLAYLIXTID-ISLYRVAYSA-N Y
|
| N (what is this?) (verify) |
Fosfestrol (trade name Honvan) is a synthetic estrogen used as an antineoplastic agent.[1]
References
- ^ Orlando, M.; Chacón, M.; Salum, G.; Chacón, D. R. (2000). "Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer". Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 11 (2): 177–181. PMID 10761752. edit
|
Estrogenics
|
|
| Receptor |
|
ER (α, β)
|
|
|
|
GPER
|
- Agonists: Estradiol
- Fulvestrant
- G-1
- Genistein
- Quercetin
- Tamoxifen
|
|
|
Enzyme
(inhibitors) |
|
20,22-Desmolase
|
- 22-ABC
- 3,3′-Dimethoxybenzidine
- 3-Methoxybenzidine
- Aminoglutethimide
- Cyanoketone
- Danazol
- Etomidate
- Mitotane
- Trilostane
|
|
|
17α-Hydroxylase,
17,20-Lyase
|
- 22-ABC
- 22-Oxime
- Abiraterone
- Bifonazole
- Clotrimazole
- Cyanoketone
- Cyproterone
- Danazol
- Econazole
- Galeterone
- Gestrinone
- Isoconazole
- Ketoconazole
- L-39
- Liarozole
- LY-207,320
- MDL-27,302
- Miconazole
- Mifepristone
- Orteronel
- Pioglitazone
- Rosiglitazone
- Spironolactone
- Stanozolol
- SU-10,603
- TGF-β
- Tioconazole
- Troglitazone
- VN/87-1
- YM116
|
|
|
3β-HSD
|
- 4-MA
- Azastene
- Cyanoketone
- Danazol
- Epostane
- Genistein
- Gestrinone
- Metyrapone
- Oxymetholone
- Pioglitazone
- Rosiglitazone
- Trilostane
- Troglitazone
|
|
|
17β-HSD
|
|
|
|
Aromatase
|
- 1,4,6-Androstatriene-3,17-dione
- 4-Androstene-3,6,17-trione
- 4-Cyclohexylaniline
- 4-Hydroxytestosterone
- 5α-DHNET
- Abyssinone II
- Aminoglutethimide
- Anastrozole
- Ascorbic acid (Vitamin C)
- Atamestane
- Bifonazole
- CGP-45,688
- CGS-47,645
- Clotrimazole
- DHT
- Difeconazole
- Econazole
- Exemestane
- Fadrozole
- Fenarimol
- Finrozole
- Formestane
- Imazalil
- Isoconazole
- Ketoconazole
- Letrozole
- Liarozole
- MEN-11066
- Miconazole
- Minamestane
- Nimorazole
- NKS01
- ORG-33,201
- Penconazole
- Plomestane
- Prochloraz
- Propioconazole
- Pyridoglutethimide
- Rogletimide
- Rotenone
- Talarozole
- Testolactone
- Tioconazole
- Triadimefon
- Triadimenol
- Troglitazone
- Vorozole
- YM511
- Zinc
Note: 5α-reductase and 21-hydroxylase inhibitors may also affect estrogen levels as they prevent metabolism of estrogen steroid precursors.
|
|
|
| Other |
|
Endogenous
|
- Estrogens: 5α-Androstane-3β,17β-diol
- DHEA
- Estetrol
- Estradiol
- Estriol
- Estrone
- Antiestrogens: 2-Hydroxyestrone
- 16-Hydroxyestrone
- Precursors: Cholesterol
- 22R-Hydroxycholesterol
- 20α,22R-Dihydroxycholesterol
- Pregnenolone
- 17-Hydroxypregnenolone
- Progesterone
- 17-Hydroxyprogesterone
- Cortodoxone/Deoxycortisol
- DHEA
- DHEA sulfate
- 16-Hydroxy-DHEA
- 16-Hydroxy-DHEA sulfate
- Androstenediol
- Androstenedione
- 16-Hydroxyandrostenedione
- Testosterone
|
|
|
Indirect
|
- Androgens/Antiandrogens (see here)
- Calcitriol (a form of Vitamin D)
- GnRH agonists/antagonists (see here)
- Gonadotropins//Antigonadotropins (see here)
- Plasma proteins (SHBG, ABP, Albumin)
- Progestogens/Antiprogestins (see here)
- Prolactin
|
|
|
Procedures
|
- Adrenalectomy
- Hypophysectomy
- Oophorectomy
- Orchiectomy
|
|
|
English Journal
- Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report.
- Wada Y1, Uchiba M, Kawano Y, Kai N, Takahashi W, Honda J, Tanoue K, Maeda Y, Murakami Y, Eto M, Imamura T.
- Journal of medical case reports.J Med Case Rep.2012 Nov 6;6:378. doi: 10.1186/1752-1947-6-378.
- PMID 23130841
- Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol.
- Qu YQ1, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM.
- Die Pharmazie.Pharmazie.2011 Mar;66(3):216-21.
- PMID 21553654
- Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
- Azuma H1, Sakamoto T, Kiyama S, Ubai T, Kotake Y, Inamoto T, Takahara K, Nishimura Y, Segawa N, Katsuoka Y.
- American journal of clinical oncology.Am J Clin Oncol.2008 Apr;31(2):188-94. doi: 10.1097/COC.0b013e3181595af6.
- PMID 18391605
Japanese Journal
- 3 bucolome併用warfarin投与法II薬物相互作用による維持量変動その四tolbutamideの増減,tetracycline,valproate sod.,fosfestrol(第246回新潟循環器談話会)
- 進行性前立腺癌に対する、内分泌化学療法 (Fosfestrol+VP16) の治療効果(第93回日本泌尿器科学会総会)
- 東 治人,坂元 武,木山 賢,丸山 栄勲,右梅 貴信,古武 弥嗣,稲元 輝生,高原 健,伊夫貴 直和,勝岡 洋治
- 日本泌尿器科學會雜誌 96(2), 344, 2005-03-05
- NAID 110004039351
- PP3-141 進行性前立腺癌に対する内分泌化学療法(TAB+Fosfestrol+VP16)の治療効果(一般演題(ポスター))
- 右梅 貴信,東 治人,坂元 武,木山 賢,木浦 宏真,丸山 栄勲,稲元 輝生,伊夫貴 直和,岩本 勇作,木下 昌重,上田 陽彦
- 日本泌尿器科學會雜誌 95(2), 509, 2004-03-15
- NAID 110003073766
Related Pictures
